|
|
||||||||
DRUG INTERACTIONS |
From Gilead Sciences, Inc, Durham, North Carolina.
The approved antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate, were considered good candidates for a fixed-dose combination product that could be administered as a single pill once daily (qd), thereby simplifying existing treatment regimens and promoting patient adherence. As both drugs are extensively renally eliminated, a randomized, 3-way crossover study was conducted in 19 healthy volunteers to formally evaluate the potential pharmacokinetic interaction when the drugs are administered alone and together (ie, 200 mg emtricitabine qd for 7 days, 300 mg tenofovir disoproxil fumarate qd for 7 days, and 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days) with no washout between treatments. Steady-state pharmacokinetic parameters (AUC
, Cmax, and Cmin) of emtricitabine and tenofovir (as tenofovir disoproxil fumarate) in combination were essentially equivalent versus each drug alone, providing a pharmacokinetic rationale for combining these products in emtricitabine/tenofovir disoproxil fumarate fixed-dose tablets.
Key Words: Emtricitabine tenofovir DF pharmacokinetics drug interaction renal elimination
Address for reprints: M. Robert Blum, PhD, Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27709; e-mail: robert.blum{at}gilead.com.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. Hirt, S. Urien, E. Rey, E. Arrive, D. K. Ekouevi, P. Coffie, S. K. Leang, S. Lalsab, D. Avit, E. Nerrienet, et al. Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1067 - 1073. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |